Merck & Co., Inc. (MRK) Financial Statements
Merck & Co., Inc. (MRK) reported trailing twelve-month revenue of $66.6B (up 4.6% year on year) and net income of $3.2B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $16.1B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MRKMerck & Co., Inc.Follow MRK — free
—
Price chart with a free account
- Market cap
- 358.4B
- P/E TTM
- 115.3
- Dividend yield
- 2.3%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2009 Dec 09 | FY2010 Dec 10 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.43 | 45.99 | 39.81 | 40.12 | 42.29 | 39.12 | 41.52 | 48.70 | 59.28 | 60.12 | 64.17 | 65.01 | 66.57 | |
| Gross profit | 18.41 | 27.59 | 25.92 | 27.35 | 28.79 | 27.11 | 27.90 | 35.08 | 41.87 | 43.99 | 48.98 | 48.63 | 48.57 | |
| Research & development | 5.85 | 11.11 | 10.26 | 10.34 | 9.75 | 9.72 | 13.40 | 12.25 | 13.55 | 30.53 | 17.94 | 15.79 | 30.45 | |
| Pre-tax income | 15.29 | 1.65 | 4.66 | 6.52 | 8.70 | 7.17 | 5.86 | 13.88 | 16.44 | 1.89 | 19.94 | 21.07 | 5.95 | |
| Income tax | 2.27 | 0.67 | 0.72 | 4.10 | 2.51 | 1.57 | 1.34 | 1.52 | 1.92 | 1.51 | 2.80 | 2.80 | 2.78 | |
| Net income | 12.90 | 0.86 | 3.92 | 2.39 | 6.22 | 9.84 | 7.07 | 13.05 | 14.52 | 0.37 | 17.12 | 18.25 | 3.17 | |
| Diluted EPS ($) | 5.65 | 0.28 | 1.41 | 0.87 | 2.32 | 3.81 | 2.78 | 5.14 | 5.71 | 0.14 | 6.74 | 7.28 | 1.26 | |
| Diluted shares (bn) | — | 3.120 | 2.787 | 2.748 | 2.679 | 2.580 | 2.541 | 2.538 | 2.542 | 2.547 | 2.541 | 2.507 | — |
USD billions · SEC XBRL
Merck & Co., Inc. — questions
- What is Merck & Co., Inc.'s revenue?
- $66.6B over the twelve months to 2026-06-30, up 4.6% year on year, from its 10-Q and 10-K filings.
- What is Merck & Co., Inc.'s net income?
- $3.2B over the twelve months to 2026-06-30.
- What is Merck & Co., Inc.'s free cash flow?
- $16.1B over the twelve months to 2026-06-30.
- What are Merck & Co., Inc.'s diluted earnings per share?
- $1.26 over the twelve months to 2026-06-30.
Every figure on this page comes from Merck & Co., Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.